ClinicalTrials.gg
Active, not recruitingNCT05283889GRATKAUpdated Feb 5, 2026

Genicular Radiofrequency Ablation Following Total Knee Arthroplasty

An interventional study of Genicular Radiofrequency Ablation and Sham Genicular Radiofrequency Ablation in Osteoarthritis, Knee, sponsored by University of Calgary. Active, not recruiting at 1 site in Canada. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-02-05.

Sponsored by University of Calgary · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 171 studies in Osteoarthritis, Knee with a site in Canada — 28 open to participants now, 40 under way, 6 of them phase 3. Osteoarthritis, Knee · Canada.

Planned enrollment
104th of 160
44 · median 63
Started
2022
with 7 others
No phase
100 of 171
19 open now
Primary completion
2026-12
later than 14 of 39 live
Registered
129th of 171
by date
Lead sponsor
8 of 171
University of Calgary

Among the 171 studies in Osteoarthritis, Knee with a site in Canada, this one is the 104th largest by planned enrollment of the 160 interventional ones that give a count, is one of 8 that started in 2022, is one of 100 with no phase, reaches primary completion later than 14 of the 39 other live ones, and was the 129th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

28 of the 171 studies in Osteoarthritis, Knee with a site in Canada are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 171 studies in Osteoarthritis, Knee with a site in Canada, or all of them as a file.
02

Study summary

Currently, nearly 1 million total knee arthroplasties (TKA) are performed yearly in the United States. Three million are projected to be performed in 2040. Between 15-30% of all patients who undergo TKA have continued pain, reduced quality of life and functional impairments that cannot be attributed to hardware failure/loosening or infection. Treatment options for persistent post TKA pain (failed TKA) are limited. There is a need for minimally invasive, and effective pain and disability modulating interventions for patients with failed TKA. Genicular radiofrequency ablation (GRFA) has been described, refined, and validated as an effective minimally invasive intervention to control refractory knee pain secondary to knee osteoarthritis (OA) as evidenced by three favorable meta-analyses published in 2021 alone.3-5 GRFA is a minimally invasive percutaneous procedure that utilizes thermal energy to coagulate nerves from the knee. Though sometimes used in practice, there is limited research describing and evaluating GRFA for patients with failed TKA. This will be the first trial to evaluate the safety and efficacy of GRFA in patients with failed TKA using a robust study design and up-to-date, evidence-based selection criteria and technique.

Read the detailed description

The general objective of this study is to determine the safety and efficacy of GRFA in patients with failed TKA. The central hypothesis is that GRFA is safe and more efficacious in improving pain and function than sham GRFA. A triple blinded randomized sham-controlled trial design will be used. Patients with failed TKA will be recruited and randomized into either a thermal or sham GRFA group. Patient selection criteria and GRFA procedural technique will incorporate refinements based on expanded understanding from recent research. Outcomes will be assessed prior to and at 3, 6 and 12 months post-GRFA. The primary outcome measures will be between group difference in the change in pain (NRS) between pre- and 6 months post. Secondary outcomes will include safety and changes in function (WOMAC; sit-stand test; strength; range of motion \& balance), participants' impression of change, perceived need for revision arthroplasty, analgesic use, and quality-of-life. Crossover will be offered to participants in the sham group at 6 months post-treatment. Data will be analyzed using descriptive, linear mixed-effects model and Kaplan-Meier Survival Curve statistics. The proposed research is innovative and important as it uses a robust study design to evaluate the safety and efficacy of an emerging RFA intervention in a prevalent suffering patient population.

03

Conditions studied

  • Osteoarthritis, Knee

Keywords

  • Genicular Radiofrequency Ablation
  • Randomized Controlled Trial
  • Knee Pain
  • Balance
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • >1 year post TKA
  • persistent knee pain > 4/10 in intensity on average over the prior week of one of the post-TKA knees
  • to conventional treatment (i.e., physiotherapy, medication, etc.)
  • ≥80% pain relief with a single fluoroscopically guided local anesthetic block using 0.5 mL of 2% lidocaine for the medial and lateral branches of the nerve to the vastus intermedialis, nerve to the vastus lateralis*, inferior medial genicular nerve, infrapatellar branch of the saphenous nerve, and the recurrent fibular nerve. 0.5 mL will be injected over 2 spots (1.5 cm apart) for each of the superior medial and lateral genicular nerves corresponding to the sites of the RF cannulae for the bipolar strip lesions. *Blocks will be combined fluoroscopy/ultrasound guided.

Exclusion criteria

Exclusion Criteria:

  • Infection (peri-prosthetic, joint, systemic, skin/soft tissue overlying the knee to be treated)
  • Prosthetic loosening or failure, periprosthetic fracture
  • Severe psychiatric disorder
  • Non-genicular lower extremity pain source from the spine (i.e., radiculopathy or neurogenic claudication) or peripheral joints (i.e., hip osteoarthritis)
  • Peripheral vascular disease causing vascular claudication
  • Connective tissue/inflammatory joint disease/widespread soft tissue pain disorder
  • Poor tolerance of injection procedures (as observed from the prognostic local anesthetic blocks)
  • Allergy to local anesthetic, synovial expansion into the anticipated path(s) of the local anesthetic needle/RF cannula as determined by ultrasound scanning
  • Uncontrolled bleeding diathesis
  • Pregnancy
  • Pacemaker or neurostimulator
  • Inability to complete Patient-Reported Outcome Measures due to cognitive or language limitations.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    Group 1 (GRFA)

    After the cannulae are placed and tines deployed, a single lesion (30 second ramp-up time; 80C x 2 minutes) will be made at each of the medial and lateral branches of the nerve to the vastus intermedialis, nerves to the vastus lateralis and medialis, recurrent fibular nerve, inferior medial genicular nerve. One bipolar strip lesion (intercannula distance 1.5 cm; anticipated strip lesion length 2.0 cm) at the superior medial and lateral genicular nerves will be made to accommodate anatomical variability.

    Procedure: Genicular Radiofrequency Ablation

  • Active comparator
    Group 2 (Sham)

    The same procedure will be employed as per Group 1 - However, the sham procedure will involve no electrical signal applied to the participant.

    Procedure: Sham Genicular Radiofrequency Ablation

Interventions

  • ProcedureGenicular Radiofrequency Ablation

    After the cannulae are placed and tines deployed, a single lesion (30 second ramp-up time; 80C x 2 minutes) will be made at each of the medial and lateral branches of the nerve to the vastus intermedialis, nerves to the vastus lateralis and medialis, recurrent fibular nerve, inferior medial genicular nerve. One bipolar strip lesion (intercannula distance 1.5 cm; anticipated strip lesion length 2.0 cm) at the superior medial and lateral genicular nerves will be made to accommodate anatomical variability.

  • ProcedureSham Genicular Radiofrequency Ablation

    After the cannulae are placed and tines deployed, a single lesion (no electrical signal applied to patient) will be made at each of the medial and lateral branches of the nerve to the vastus intermedialis, nerves to the vastus lateralis and medialis, recurrent fibular nerve, inferior medial genicular nerve. One bipolar strip lesion (intercannula distance 1.5 cm; anticipated strip lesion length 2.0 cm) at the superior medial and lateral genicular nerves will be made to accommodate anatomical variability.

06

What researchers measure

Primary outcomes

  1. Average Pain Intensity Over the Prior week (0 - 10)

    Numerical pain rating scale (0 - 10) with higher scores indicating a worse outcome

    Time frame: 6 months

  2. Change in pain intensity between pre- and 6-months post-intervention

    Numerical Pain rating scale (NPRS) 6 month minus NPRS pre-intervention, with increased negative scores indicating a better outcome

    Time frame: 6 months

Secondary outcomes

  1. Average Pain Intensity Over the Prior Week (0 - 10)

    Numerical pain rating scale (0 - 10) with higher scores indicating worse outcomes

    Time frame: 3 and 12-months post-intervention

  2. Western Ontario and McMaster Universities Arthritis Index (WOMAC)

    Measure of pain (0 - 20), stiffness (0 - 8) and physical function (0 - 68) with higher scores indicating wore pain, stiffness and functional limitations

    Time frame: 3, 6 and 12-months post-intervention

  3. The Clinical Global Impressions Scale (CGI)

    Patient reported global impression of change (1 = Very Much Improved to 7 = Very Much Worse)

    Time frame: 3, 6 and 12-months post-intervention

  4. Safety - Adverse Events

    Presence of self-reported complications

    Time frame: 1-week, 3, 6 and 12-months post-intervention

  5. Proportion of participants exceeding 50% pain relief

    Proportion of participants that experience ≥ 50% pain relief

    Time frame: 6 months

  6. Proportion of participants exceeding Minimal Clinically Important Difference (MCID) pain relief

    Proportion of participants that experience MCID knee pain relief

    Time frame: 6 months

  7. Perceived Need for Revision Arthroplasty

    "If revision surgery of your knee replacement was available to you, how interested would you be in having it at this time?" Y or N

    Time frame: Baseline (Prior to), 3, 6 and 12-months post-intervention

  8. Analgesic Use

    Quantitative Analgesic Questionnaire

    Time frame: Baseline (Prior to), 3, 6 and 12-months post-intervention

  9. Health-related Quality of Life

    EQ-5D-5L

    Time frame: Baseline (Prior to), 3, 6 and 12-months post-intervention

07

Study locations

1 site
08

References and documents

Publications

  • Singh JA, Yu S, Chen L, Cleveland JD. Rates of Total Joint Replacement in the United States: Future Projections to 2020-2040 Using the National Inpatient Sample. J Rheumatol. 2019 Sep;46(9):1134-1140. doi: 10.3899/jrheum.170990. Epub 2019 Apr 15. PubMed 30988126 ↗
  • Beswick AD, Wylde V, Gooberman-Hill R, Blom A, Dieppe P. What proportion of patients report long-term pain after total hip or knee replacement for osteoarthritis? A systematic review of prospective studies in unselected patients. BMJ Open. 2012 Feb 22;2(1):e000435. doi: 10.1136/bmjopen-2011-000435. Print 2012. PubMed 22357571 ↗
  • Zhang H, Wang B, He J, Du Z. Efficacy and safety of radiofrequency ablation for treatment of knee osteoarthritis: a meta-analysis of randomized controlled trials. J Int Med Res. 2021 Apr;49(4):3000605211006647. doi: 10.1177/03000605211006647. PubMed 33887985 ↗
  • Li G, Zhang Y, Tian L, Pan J. Radiofrequency ablation reduces pain for knee osteoarthritis: A meta-analysis of randomized controlled trials. Int J Surg. 2021 Jul;91:105951. doi: 10.1016/j.ijsu.2021.105951. Epub 2021 Apr 18. PubMed 33882358 ↗
  • Chen AF, Mullen K, Casambre F, Visvabharathy V, Brown GA. Thermal Nerve Radiofrequency Ablation for the Nonsurgical Treatment of Knee Osteoarthritis: A Systematic Literature Review. J Am Acad Orthop Surg. 2021 May 1;29(9):387-396. doi: 10.5435/JAAOS-D-20-00522. PubMed 32701684 ↗
  • Protzman NM, Gyi J, Malhotra AD, Kooch JE. Examining the feasibility of radiofrequency treatment for chronic knee pain after total knee arthroplasty. PM R. 2014 Apr;6(4):373-6. doi: 10.1016/j.pmrj.2013.10.003. Epub 2013 Dec 27. PubMed 24373908 ↗
  • Kapural L, Lee N, Neal K, Burchell M. Long-Term Retrospective Assessment of Clinical Efficacy of Radiofrequency Ablation of the Knee Using a Cooled Radiofrequency System. Pain Physician. 2019 Sep;22(5):489-494. PubMed 31561648 ↗
  • Koshi E, Cheney CW, Sperry BP, Conger A, McCormick ZL. Genicular Nerve Radiofrequency Ablation for Chronic Knee Pain Using a Three-Tined Electrode: A Technical Description and Case Series. Pain Med. 2020 Dec 25;21(12):3344-3349. doi: 10.1093/pm/pnaa204. PubMed 32984887 ↗
  • Erdem Y, Sir E. The Efficacy of Ultrasound-Guided Pulsed Radiofrequency of Genicular Nerves in the Treatment of Chronic Knee Pain Due to Severe Degenerative Disease or Previous Total Knee Arthroplasty. Med Sci Monit. 2019 Mar 12;25:1857-1863. doi: 10.12659/MSM.915359. PubMed 30858350 ↗
  • Qudsi-Sinclair S, Borras-Rubio E, Abellan-Guillen JF, Padilla Del Rey ML, Ruiz-Merino G. A Comparison of Genicular Nerve Treatment Using Either Radiofrequency or Analgesic Block with Corticosteroid for Pain after a Total Knee Arthroplasty: A Double-Blind, Randomized Clinical Study. Pain Pract. 2017 Jun;17(5):578-588. doi: 10.1111/papr.12481. Epub 2016 Sep 19. PubMed 27641918 ↗
  • Fonkoue L, Steyaert A, Kouame JK, Bandolo E, Lebleu J, Fossoh H, Behets C, Detrembleur C, Cornu O. A Comparison of Genicular Nerve Blockade With Corticosteroids Using Either Classical Anatomical Targets vs Revised Targets for Pain and Function in Knee Osteoarthritis: A Double-Blind, Randomized Controlled Trial. Pain Med. 2021 May 21;22(5):1116-1126. doi: 10.1093/pm/pnab014. PubMed 33772285 ↗
  • Tran J, Peng PWH, Lam K, Baig E, Agur AMR, Gofeld M. Anatomical Study of the Innervation of Anterior Knee Joint Capsule: Implication for Image-Guided Intervention. Reg Anesth Pain Med. 2018 May;43(4):407-414. doi: 10.1097/AAP.0000000000000778. PubMed 29557887 ↗
  • Cushman DM, Monson N, Conger A, Kendall RW, Henrie AM, McCormick ZL. Use of 0.5 mL and 1.0 mL of Local Anesthetic for Genicular Nerve Blocks. Pain Med. 2019 May 1;20(5):1049-1052. doi: 10.1093/pm/pny277. No abstract available. PubMed 30590798 ↗
  • Roos EM, Klassbo M, Lohmander LS. WOMAC osteoarthritis index. Reliability, validity, and responsiveness in patients with arthroscopically assessed osteoarthritis. Western Ontario and MacMaster Universities. Scand J Rheumatol. 1999;28(4):210-5. doi: 10.1080/03009749950155562. PubMed 10503556 ↗
  • Kreibich DN, Vaz M, Bourne RB, Rorabeck CH, Kim P, Hardie R, Kramer J, Kirkley A. What is the best way of assessing outcome after total knee replacement? Clin Orthop Relat Res. 1996 Oct;(331):221-5. doi: 10.1097/00003086-199610000-00031. PubMed 8895642 ↗
  • Grafton ST, Ralston AB, Ralston JD. Monitoring of postural sway with a head-mounted wearable device: effects of gender, participant state, and concussion. Med Devices (Auckl). 2019 May 1;12:151-164. doi: 10.2147/MDER.S205357. eCollection 2019. PubMed 31118838 ↗
  • Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007 Jul;4(7):28-37. PubMed 20526405 ↗
  • Robinson-Papp J, George MC, Wongmek A, Nmashie A, Merlin JS, Ali Y, Epstein L, Green M, Serban S, Sheth P, Simpson DM. The Quantitative Analgesic Questionnaire: A Tool to Capture Patient-Reported Chronic Pain Medication Use. J Pain Symptom Manage. 2015 Sep;50(3):381-6. doi: 10.1016/j.jpainsymman.2015.03.013. Epub 2015 Apr 23. PubMed 25912277 ↗
  • Balestroni G, Bertolotti G. [EuroQol-5D (EQ-5D): an instrument for measuring quality of life]. Monaldi Arch Chest Dis. 2012 Sep;78(3):155-9. doi: 10.4081/monaldi.2012.121. Italian. PubMed 23614330 ↗
  • Kim SY, Le PU, Kosharskyy B, Kaye AD, Shaparin N, Downie SA. Is Genicular Nerve Radiofrequency Ablation Safe? A Literature Review and Anatomical Study. Pain Physician. 2016 Jul;19(5):E697-705. PubMed 27389113 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Dec 2026, 55 months after the start.

Of 1,114 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 55 months is above that.

Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2022
First posted
Mar 17, 2022
StartActual
May 11, 2022
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Feb 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05283889
Responsible party
Sponsor
First posted
Mar 17, 2022
Start date
May 11, 2022
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Feb 5, 2026

Study contacts

Ashley Smith, PhD
principal investigator · University of Calgary

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion